This website has been developed and fully funded by Janssen-Cilag Ltd. and is intended for UK patients prescribed Tremfya®▼ (guselkumab) only.

Information on COVID-19 for patients using Tremfya® (guselkumab)
FAQ

A. Discuss with your healthcare professional before you have any vaccinations. Live vaccines should not be given during treatment with this medication, whether viral or bacterial, such as BCG (Bacillus Calmette–Guérin). Treatment should be stopped for at least 12 weeks after the last dose before receiving a live vaccination and resumed no less than two weeks after.3

You may be given inactivated or non-live vaccinations while using this medicine.3

A. If you want to become pregnant, discuss this with your doctor. The effects of administering this medication while pregnant are not known.1

Women of childbearing potential should use effective methods of contraception during treatment and for at least 12 weeks after treatment.1

If you become pregnant, contact your healthcare professional immediately.1

A. Using this medication while undergoing surgery may increase your risk of a post-operative infection. If you need to arrange surgery or have surgery planned, make sure you discuss this with your doctor.2

A. There are no known interactions with drinking alcohol while using this medicine.2 However, if you drink or smoke excessively, it would be beneficial to reduce this. Speak to your healthcare professional if you would like advice or support in doing this.

A. Where available, all patients are eligible for the Homecare Service. To sign up, discuss the type of service that is appropriate for you with your doctor. You will both complete forms to begin the registration process.

A. No – you may prefer to receive continued nursing support to administer the medication at home. However, only a small number of patients generally require this. You may want to choose this option if you are scared of needles or have problems with using your hands effectively.

A. If you would like to stop using this medicine you should discuss this with your doctor.1 They will advise you on the best way to do this.

A. Your treatment must be kept out of sight and reach of children. It should be kept in a fridge (at 2 - 8°C) and in its original carton to protect it from light. Do not freeze or shake your pre-filled pen as this can damage the medication. Make sure that you remove the pen from the fridge, without removing it from the carton, half an hour before you intend to inject it so that it can reach room temperature.1

For detailed information on how to store, prepare, or dispose of your treatment please see the Patient Information Leaflet.

A. If you think you have left your medicine out of the fridge for too long, contact your healthcare professional as soon as possible for advice.

A. After your first two doses at weeks 0 and 4, the recommended treatment dose needs to be administered once every 8 weeks.1 Therefore, if you travel between your scheduled doses you won’t need to take your medication with you. Please discuss with your dermatologist if you are planning to travel abroad. Depending on where you are travelling, precautions may need to be taken against infections.2

A. If you have any questions about your treatment not covered here or in the available resources, make sure you speak to your doctor, nurse or pharmacist.

Reporting side effects

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also call Janssen-Cilag Ltd Drug Safety on 01494 567447 or at dsafety@its.jnj.com.

By reporting side effects you can help provide more information on the safety of this medicine.

References

  1. Tremfya® Patient Information Leaflet. Available from: https://www.medicines.org.uk/emc/files/pil.9587.pdf [Last accessed March 2021].
  2. British Association of Dermatologists: Guselkumab. Available from: https://www.bad.org.uk/shared/get-file.ashx?id=6337&itemtype=document [Last accessed March 2021].
  3. Janssen-Cilag Ltd. Tremfya® (guselkumab) Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc [Last accessed March 2021].